X4 Pharmaceuticals Inc.

04/29/2024 | Press release | Distributed by Public on 04/29/2024 04:38

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome